Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus
  • Home
  • /
  • Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus
  1. Home /
  2. Archives /
  3. Vol. 8 No. 12 (2018) /
  4. Research Articles

Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus

Authors

  • Mirella Czapska Scientific Society at the Department of Human Physiology, Medical University of Lublin
  • Kamila Babkiewicz Scientific Society at the Department of Human Physiology, Medical University of Lublin
  • Szczepan Pabis Departament of Urology University of Rzeszów
  • Katarzyna Skórzyńska-Dziduszko Department of Human Physiology, Medical University of Lublin

Keywords

SGLT1 and SGLT2 inhibitor, sotagliflozin, type 1 diabetes (T1D), HbA1C, hypoglycemia

Abstract

Sotagliflozin (SOTA) is a dual inhibitor of SGLT1 and SGLT2 used in adults with type 1 diabetes. The mechanism of action, based on the inhibition of both the SGLT1 and SGLT2 cotransporters, allows simultaneous increase of glucose excretion and slowing down the absorption of glucose in the intestine. Recently, test results have been published showing a beneficial effect of sotagliflozin on type 1 diabetes control [1,2,3]. Sotagliflozin use leads to a significant reduction in glycosylated haemoglobin (HbA1c) [1,2,3] , postprandial glucose reduction [1,2,3], weight loss [1,2,3],  systolic blood pressure reduction  [1,2,3] and reducing the risk of hypoglycaemia during the treatment [1,2,3]. Treatment of type 1 diabetes is based on a model of intensive, functional insulin therapy with the use of human insulin preparations or analogues of this insulin [10]. The therapy is carried out by multiple, subcutaneous injections of insulin doses or in the form of continuous insulin infusion with a personal insulin pump [10]. According to the recommendations of the Polish Diabetes Association (PTD) for patients with type 1 diabetes in terms of glycemic control, the primary goal is to maintain HbA1C  7% (53mmol / mol) and when the goal is not associated with the risk of hypoglycaemia, the target value is  6.5%. The use of proper treatment and sustaining HbA1C at the level recommended by PTD allows to prevent acute and chronic complications of the disease and at the same time allows patients to live actively and, consequently, improves their life quality [10]. According to recently published studies, preparations from SGLT-1 and SGLT-2 inhibitor groups may be helpful in obtaining and sustaining the treatment objective recommended by PTD.

Downloads

  • PDF

Published

2018-12-14

How to Cite

1.
CZAPSKA, Mirella, BABKIEWICZ, Kamila, PABIS, Szczepan & SKÓRZYŃSKA-DZIDUSZKO, Katarzyna. Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus. Journal of Education, Health and Sport [online]. 14 December 2018, T. 8, nr 12, s. 335–351. [accessed 30.3.2023].
  • PN-ISO 690 (Polish)
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 8 No. 12 (2018)

Section

Research Articles

License

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 93
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

SGLT1 and SGLT2 inhibitor, sotagliflozin, type 1 diabetes (T1D), HbA1C, hypoglycemia
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Karmelitański Instytut Duchowości w Krakowie
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop